The addition of Kynamro helps to reduce low-density lipoprotein-cholesterol (LDL-C), apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol (non HDL-C).
FORBES: FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemia
Statins help lower low-density lipoprotein cholesterol, or "bad" cholesterol.
KYNAMRO, given as a 200 mg weekly subcutaneous injection, has been approved as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (Apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).
FORBES: FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemia
Torcetrapib aims to raise good cholesterol, or high-density lipoprotein, by blocking the cholesterol ester transfer protein.
Low-density lipoprotein, the bad cholesterol, carries cholesterol fat to the arteries, where it gets stored as plaque in the artery wall.
Low-density lipoprotein (LDL) or bad cholesterol levels should be below 100, and high-density lipoprotein (HDL) should measure 35 or above.
These studies had led to new cholesterol guidelines in the U.S. that suggested lowering low-density lipoprotein (LDL), or bad cholesterol, to extemely low levels.
High-density lipoprotein is thought to carry the cholesterol from the artery wall to the liver for disposal.
The medicine worked incredibly well, lowering low-density lipoprotein (LDL), the bad cholesterol, by 70%.
FORBES: How A Mourning Entrepreneur And A Dogged Doctor Rescued A Rare Disease Drug
ETC-216 is a slightly different version of a protein in high-density lipoprotein, the so-called good cholesterol.
"Bad" cholesterol - or low density lipoprotein - can block arteries and cause heart disease.
Alcohol, including beer, in moderation raises high-density lipoprotein or HDL, known as good cholesterol, says Dr. R.
"I'm confused, " he says, because reducing low-density lipoprotein (LDL), or bad cholesterol, is such a cornerstone of cardiology.
Both work by inhibiting an obscure molecule called the cholesterol ester transfer protein (CETP) that works indirectly to prevent HDL from being used to create low-density lipoprotein (LDL), the bad cholesterol.
Researchers speculating about what went wrong thought perhaps torcetrapib made HDL that didn't work, or that HDL itself (short for high-density lipoprotein, and often called "good cholesterol") was less powerful than they thought.
Zetia (generically known as ezetimibe) lowers low-density lipoprotein (LDL), the bad cholesterol involved in causing heart attacks and strokes, but less so than existing drugs like Lipitor (generically known as atorvastatin), Crestor, from AstraZeneca, or simvastatin.
FORBES: Merck's Cholesterol Pill Win Is Already Drawing Fire
But when Zetia was combined with a statin like Lipitor or Zocor, it lowered bad cholesterol, or low-density lipoprotein (LDL), more than anything else out there.
The drug is designed to boost high-density lipoprotein (HDL), nicknamed "good cholesterol" because it appears to actually clear plaque from the arteries and reduce the risk of heart attack.
For the company's finances, the most important new drug is torcetrapib, a new medicine designed to raise high-density lipoprotein (HDL), the "good cholesterol, " which is thought to help clear plaque from the arteries.
It also lowered the so-called good cholesterol, or high-density lipoprotein (HDL), and it did not enter the cell, a characteristic Medford wanted hisdrug to have, because some of the oxidation process takes place within cellular membranes.
In Ridker's study, patients with high bad cholesterol, or low-density lipoprotein and high CRP had heart attacks, strokes or heart procedures 9.9% of the time compared with 4.9% of the time for patients where both risks were low.
In the study where it helped patients lose weight, the drug also raised good cholesterol, or high-density lipoprotein (HDL), by 23%, almost as much as Niaspan, the sustained-release niacin drug made by Kos Pharmaceuticals (nasdaq: KOSP - news - people ) that is the main currently available treatment for raising HDL. Rimonabont also cut triglycerides, another risk factor for heart disease, by 16%.
High-density lipoprotein, better known as HDL or "good cholesterol, " has become a medical mainstay.
Nothing on the market today increases "good cholesterol, " or high-density lipoprotein (HDL), as much as torcetrapib did in early clinical trials.
Coronary artery disease begins when excess cholesterol particles, called low-density lipoprotein particles, become lodged in the artery wall over time and get chemically damaged, or oxidized (close-up diagram).
For patients at the highest risk of heart attack, the new guidelines suggest that "bad cholesterol, " or low-density lipoprotein (LDL), be reduced to 70 mg per deciliter--although the new guideline is optional.
Schering and Merck have defended the drugs by pointing to the mountains of evidence that support the idea that lowering low-density lipoprotein, commonly known as LDL or "bad cholesterol, " prevents heart attacks.
Most of the time low-density lipoprotein (LDL), better known as "bad cholesterol, " sits around doing little.
For a few years it thought it had one: good cholesterol, also known as high-density lipoprotein.
Up until now, evidence for statins has been mainly in people with high "bad" cholesterol, properly known as low-density lipoprotein (LDL).
应用推荐